News >

T-DM1 May Provide Less-Toxic Option in Older HER2+ Breast Cancer Population

Angelica Welch
Published: Friday, Dec 14, 2018

Akihiko Shimomura, MD, PhD

Akihiko Shimomura, MD, PhD

Elderly patients with HER2-positive breast cancer remain a clinical unmet need, according to Akihiko Shimomura, MD, PhD, making the development of clinical trials for this population an important aspect of breast cancer research.

, Shimomura, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discussed the rationale for this study of elderly patients with HER2-positive breast cancer.

OncLive: Please give an overview of the HERB TEA study.

Shimomura: This is a randomized phase III study comparing T-DM1 with combination therapy of HPD in elderly patients with advanced-stage HER2-positive breast cancer. This is a noninferiority study, and the sample size is 330. It is sponsored by the Japan Clinical Oncology Group, and 43 institutes in Japan contributed to this study.

Elderly patients often have comorbidities. Some elderly patients are not fit to undergo toxic therapy, such as HPD. The aim of our study is to develop a less-toxic novel treatment for elderly patients with advanced HER2-positive breast cancer.

How could the findings impact the HER2-positive breast cancer paradigm?

There have been a few studies targeting elderly patients with breast cancer. Only 50% of patients over the age of 65 [with HER2-positive breast cancer] participated in the CLEOPATRA study. In the clinic, we feel that HPD is too toxic for elderly patients. It is unclear how to optimally treat elderly patients with advanced-stage HER2-positive breast cancer, so we planned this study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication